REGENXBIO appoints Greg Ciongoli to board; two directors retire effective Aug 25, 2026

REGENXBIO Inc.

Ciongoli elected as independent Class II director, term expires at 2029 annual meeting.
Granted initial equity award with $550,000 fair value (75% option, 25% RSUs), exercise price $8.91, 3-year vesting.
Annual board retainer of $45,000 plus $10,000 audit and $5,000 nominating committee retainers.
Jean Bennett and Jerry Karabelas resigned as directors; will serve as advisors until February 2027.
Board size reduced to nine directors effective immediately.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.